Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Percutaneous radiofrequency ablation is a commonly treatment for patients with liver cancer
that cannot be surgically resected. During the procedure, patients need to keep awake and
cooperate with the procedure, including deep breath and hold breath. However, intolerable
pain generated during puncture and radiofrequency heating may cause body movements and
interfere the procedure. Oxycodone is frequently used for analgesia but still insufficient. A
recent study showed that dexmedetomidine-esketamine combination improves analgesia without
increasing adverse events. After stopping infusion, the analgesic/sleep-promoting effects of
dexmedetomidine-esketamine seemed to last for up to 24 hours.
The investigators hypothesize that dexmedetomidine-esketamine combination as a supplement to
oxycodone will improve sedation and analgesia in patients undergoing radiofrequency liver
ablation of the liver.